NDAORALTABLET
Approved
Dec 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
ADVIL PM (advil pm) by GSK is cyclooxygenase inhibitors [moa]. First approved in 2005.
Drug data last refreshed 7h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ADVIL PM is an oral tablet combining ibuprofen (NSAID) with a sleep aid, designed to relieve pain while promoting sleep through cyclooxygenase inhibition. It is an over-the-counter combination product used for nighttime pain relief, particularly for minor aches and pains that interfere with sleep.
LOE Approaching
Approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting contracted brand team and focus on retention strategies rather than growth initiatives.
Mechanism of Action
Cyclooxygenase Inhibitors
Pharmacologic Class:
Nonsteroidal Anti-inflammatory Drug
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
ADVIL PM currently shows zero linked job openings, reflecting its mature LOE-approaching status and likely contracted team size at GSK. Roles in this product typically focus on defensive brand management, retail channel relationships, and competitive pricing rather than innovation or market expansion.
Brand ManagerProduct Manager
Worked on ADVIL PM at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.